ALCLS Share Price Performance
€3.73
2.24 (150.00%)
42.6% undervalued intrinsic discount
€6.50
Fair Value
Price €3.73
AnalystConsensusTarget €6.50
Fair Value€6.50
Share Pricen/a
Cellectis S.A. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 2 Fair Values set on narratives written by author
ALCLS Community Narratives
AN
Fair Value €6.5 42.6% undervalued intrinsic discount
Allogeneic CAR T Pipeline And AstraZeneca Partnership Will Drive Long-Term Upside
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Allogeneic CAR T Pipeline And AstraZeneca Partnership Will Drive Long-Term Upside
Catalysts About Cellectis Cellectis is a clinical stage biotechnology company developing allogeneic CAR T cell therapies and in vivo gene editing solutions for hard to treat cancers and genetic disorders. What are the underlying business or industry changes driving this perspective?Read more
6
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
€6.5
42.6% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
-0.82% p.a.
Profit Margin
41.15%
Future PE
20.28x
Price in 2028
€7.91
Trending Discussion
Recently Updated Narratives
AN
Allogeneic CAR T Pipeline And AstraZeneca Partnership Will Drive Long-Term Upside
Fair Value: €6.5 42.6% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Cellectis S.A. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -0.49
- 100.00%
- -42.83%
- 51.0%
About ALCLS
- Founded
- 1999
- Employees
- 219
- CEO
- WebsiteView website
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, a gene-edited allogeneic CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin’s lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company was founded in 1999 and is headquartered in Paris, France.
